Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
Winston
Alan
A
Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Pozniak
Anton
A
Mandalia
Sundhiya
S
Gazzard
Brian
B
Pillay
Deenan
D
Nelson
Mark
M
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016049:Didanosine / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D009705:Nucleosides / Q000235:genetics; D009711:Nucleotides / Q000235:genetics; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D015995:Prevalence; D000068698:Tenofovir; D000099227:Abacavir
D000225:Adenine; D016049:Didanosine; D015224:Dideoxynucleosides; D054303:HIV Reverse Transcriptase; D009705:Nucleosides; D009711:Nucleotides; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000099227:Abacavir